3 of the Best Stocks Under $100 to Buy in 2026

The piece highlights three attractively valued, dividend-paying stocks under $100: Novo Nordisk, Comcast, and AT&T. Novo Nordisk shares fell 41% in 2025 but trade around $55 with a forward P/E of ~14 and a 3.3% yield, and the company launched an oral GLP‑1 obesity pill amid prior guidance cuts tied to knock‑off competition. Comcast trades near $28 with a forward P/E of ~7 and a 4.5% yield after spinning off noncore assets into Versant to refocus on streaming, broadband, parks and wireless. AT&T trades ~ $25 with a forward P/E ~11, yields ~4.5%, and is expanding fiber via the planned acquisition of Lumen’s Mass Markets fiber to reach ~60 million locations by 2030.

Analysis

Market structure: Winners if current narratives play out are NVO (GLP‑1 oral scale) and cash‑generative dividend names CMCSA and T; losers include niche suppliers/compounding pharmacies (short term) and legacy content players unable to monetize streaming. Oral GLP‑1 expands total addressable market and lowers per‑unit COGS, pressuring pricing power of incumbents with injectable-only portfolios and potentially increasing generic/knockoff risk. Cross‑asset: stronger NVO fundamentals would tighten its credit spreads and lift DKK FX marginally; income‑seeking flows into CMCSA/T could compress demand for long‑duration sovereign bonds and reduce equity option skew for these tickers.

Risk assessment: Tail risks include an FDA/EMA safety signal or reimbursement clampdown for GLP‑1s, regulatory action against compounding pharmacies that may take 30–180 days, or telecom fiber capex overruns breaching FCF guidance. Near term (days–weeks) sentiment will hinge on prescription/sales datapoints and earnings calls; medium term (3–12 months) on guidance/launch uptake; long term (2–5 years) on payer pricing and fiber monetization. Hidden dependencies: payer negotiations, manufacturing scale constraints for oral pills, and AT&T’s ability to integrate Lumen assets without margin erosion.

Trade implications: Size conservative long exposure to NVO (1–3% portfolio) via 9–18 month call spreads to cap premium; buy CMCSA for yield (2–4%) and sell 3–6 month covered calls at ~25–30% upside to enhance yield; hold T as a 2–3% core dividend position with 12‑month protective puts if yield curve steepens. Pair trade: long CMCSA vs short NFLX (equal notional 1% each) to play value vs growth re‑rating risk; if NVO fails to regain $50 within 90 days, cut exposure by half.

Contrarian angles: Consensus underestimates the speed at which oral GLP‑1s can commoditize pricing—if pill manufacturing scales, margins could compress industry‑wide, hurting long‑dated revenue multiples. Conversely, the market may be too pessimistic on CMCSA/T balance‑sheet optionality post‑spin and fiber M&A; historical parallels include pharma rebounds after compounding crackdowns (J&J‑era playbook). Unintended consequences: dividend seekers could be exposed to a rate shock that devalues high‑yield equities even if fundamentals hold.

Key Decisions for Investors

• Establish a 1.5–3% long position in NVO via a 9–18 month call‑spread (buy ATM call, sell 20–30% OTM call) to participate in a potential 30–50% recovery while capping premium; scale in on dips below $50 and cut position by 50% if shares stay < $50 for 90 days or if FDA/EMA issues arise.
• Buy CMCSA as a 2–4% dividend income position; immediately sell 3–6 month covered calls with strikes ~25–30% above current ($~35 strike if stock is $28) to boost yield, and increase allocation to 4–6% only after verifiable execution on Versant spin synergies in next two quarters.
• Allocate 2–3% to AT&T (T) as a fiber‑growth dividend play but purchase 12‑month puts 5% OTM to limit downside (cost financed by selling 3–6 month OTM calls) if macro yields spike; trim if fiber integration capex guidance increases >20% vs current plan.
• Execute a small relative‑value pair: long 1% CMCSA vs short 1% NFLX to exploit valuation spread (CMCSA P/E ~7 vs NFLX premium); rebalance if spread narrows <10 P/E points or if NFLX reports accelerating ARPU in next quarter.
• Monitor three specific catalysts and act: (a) FDA/EMA GLP‑1 safety/reimbursement notices (0–90 days) — positive => increase NVO to 4–5%; negative => exit NVO. (b) Comcast quarterly update on Versant synergies (next 1–2 quarters) — beat => add 1–2%. (c) AT&T/Lumen integration costs disclosure within 12 months — cost overruns >$1bn => reduce T exposure by 50%.